AVTE Insider Trading Activity and SEC Form 4 Filings
AVTE insider trading summary
No open-market insider purchases or sales of Aerovate Therapeutics, Inc. (AVTE) have been reported on SEC Form 4 in the past 12 months.
Latest AVTE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 17, 2024 | RA Capital Healthcare Fund LP | Director | Buy | $1.5M (928,110 @ $1.67) |
| Jun 17, 2024 | Peter Kolchinsky | Director | Buy | $1.5M (928,110 @ $1.67) |
| Jun 17, 2024 | Rajeev M. Shah | Director | Buy | $1.5M (928,110 @ $1.67) |
| Jun 17, 2024 | RA Capital Nexus Fund, L.P. | Director | Buy | $1.5M (928,110 @ $1.67) |
| Jun 17, 2024 | Ra Capital Management, L.P. | Insider | Buy | $1.5M (928,110 @ $1.67) |
| Jun 14, 2024 | Marinus Verwijs | Chief Technical Officer | Sell | $265K (10,600 @ $25.00) |
| Jun 14, 2024 | George A Eldridge | See Remarks | Sell | $375K (15,000 @ $25.03) |
| Jun 13, 2024 | Hunter Gillies | Chief Medical Officer | Sell | $147K (6,000 @ $24.50) |
| May 17, 2024 | Hunter Gillies | Chief Medical Officer | Sell | $2K (86 @ $21.86) |
| May 17, 2024 | Hunter Gillies | Chief Medical Officer | Sell | $82K (3,914 @ $21.07) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.